Iovance (IOVA) Shares New Amtagvi Data, Analysts Stay Positive

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) is one of the 13 Best American Penny Stocks to Invest In. On February 6, H.C. Wainwright reiterated its Buy rating on Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) with a price target of $9 on the stock. This update followed the company’s February 5 announcement of data showing a best-in-class profile for its commercial therapy Amtagvi (lifileucel). Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) shared that the treatment delivered unprecedented response rates in a re ...